Edgewise Therapeutics Q2 net loss widens to $57.3 million; Servier sale closed
Edgewise Therapeutics reported a second-quarter 2026 net loss of $57.3 million, or $0.53 per share, up from $36.1 million, or $0.34 per share, a year earlier, as research and development and general and administrative costs rose. The company completed the sale of sevasemten and its muscular dystrophy business to Servier on July 10, 2026, for $1.55 billion in upfront cash, which the company says leaves it with a pro forma balance of $2,010.7 million before taxes and transaction costs, versus $460.7 million at June 30, 2026.
Key points
- Net loss of $57.3 million ($0.53 per share) for Q2 2026, compared with $36.1 million ($0.34 per share) for Q2 2025
- R&D expenses rose to $47.5 million from $33.6 million; G&A expenses rose to $14.4 million from $9.1 million
- Cash, cash equivalents and marketable securities were $460.7 million at June 30, 2026; pro forma balance of $2,010.7 million including $1,550.0 million upfront sale proceeds
- Company expects to start a Phase 3 CIRRUS-HCM trial of EDG-7500 in Q4 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.